论文部分内容阅读
目的探讨比阿培南治疗慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)Anthonisen I型或需要有创或无创通气的患者的临床疗效及安全性。方法将68例患者分为2组:实验组32例应用比阿培南治疗,对照组36例用亚胺培南/西司他丁治疗,连续检测C-反应蛋白(C-reactive pro-tein,CRP)水平,比较2组临床疗效及细菌清除率,并了解其安全性。结果实验组:临床痊愈率为71.8%,临床有效率为90.6%,细菌清除率为90.9%;对照组:临床痊愈率为66.7%,临床有效率为86.1%,细菌清除率为78.3%;均未见严重不良反应。经治疗后CRP均下降明显,治疗第3天实验组25例CRP下降50%,对照组28例CRP下降50%,差异无统计学意义。结论比阿培南治疗AECOPD Anthonisen I型或需要有创或无创通气的患者感染疗效迅速、确切,副作用小。
Objective To investigate the clinical efficacy and safety of biapenem in the treatment of patients with chronic exacerbation of chronic obstructive pulmonary disease (Anthonisen I) or patients with invasive or noninvasive ventilation. Methods Sixty-eight patients were divided into two groups: 32 cases in the experimental group were treated with biapenem, 36 cases in the control group were treated with imipenem / cilastatin, C-reactive protein (C-reactive protein , CRP) levels were compared between two groups of clinical efficacy and bacterial clearance, and understand the safety. Results In the experimental group, the clinical cure rate was 71.8%, the clinical effective rate was 90.6% and the bacterial clearance rate was 90.9%. In the control group, the clinical cure rate was 66.7%, the clinical effective rate was 86.1% and the bacterial clearance rate was 78.3% No serious adverse reactions. After treatment, the CRP decreased significantly. On the third day after treatment, the CRP in the experimental group decreased by 50% and the CRP in the control group decreased by 50%. There was no significant difference between the two groups. Conclusions Biapenem treatment of AECOPD Anthonisen type I or in patients with invasive or noninvasive ventilation is rapid, precise and with minimal side effects.